IMDxInc

IMDxInc iMDx is dedicated to advancing precision medicine.

Our mission is to democratize access to cutting-edge diagnostic solutions by making precision medicine more widely available through both clinical testing and research-driven collaborations. iMDx: Precision Diagnostics for Oncology & Transplantation
Science with Purpose
At iMDx, we believe that innovation must be matched with integrity and compassion. Our CLIA-certified and CAP-accredited laborat

ories uphold the highest standards, ensuring that every result we deliver is accurate, reliable, and clinically meaningful. By making advanced molecular diagnostics more accessible, we are shaping a future where early detection, personalized treatment, and better patient outcomes are the norm.

01/22/2026

We’re officially on the floor at American Society of Transplant Surgeons - ASTS Winter Symposium 2026!

Come say hi to the IMDxInc team at Booth 305 — we’re excited to connect and talk donor-derived cfDNA testing.

For more information visit: https://6363663.hs-sites.com/asts2026

01/15/2026

We’re headed to American Society of Transplant Surgeons (ASTS) Winter Symposium 2026 — and we’d love to see you there!

Join us for our symposium to kick off the meeting!

In-House dd-cfDNA Testing: Giving Surgeons Control, featuring Kenneth Andreoni, MD (Surgical Director, Kidney Transplantation, Thomas Jefferson University Hospital).

➡️ Lunch is on us! 🍽️
🗓 Thursday, January 22
🕦 11:30 AM – 12:30 PM
📍 Komatke E/F/G

Stop by our booth ( #305) to connect, learn more about GraftAssureCore, our new clinical registry, and see how dd-cfDNA testing powered by droplet-digital PCR can support confident, timely decision-making in transplant care.

Steven Tahmooressi
ScottHenderson
Paul Muncy
Dan Lindsay
Jason H. McDowell
Ryan Andrews
Nick Ioannou, M.D., PhD, MHA

This week, IMDxInc attended the Q1 productions diagnostic coverage and reimbursement meeting held in Boston. It was gr...
12/12/2025

This week, IMDxInc attended the Q1 productions diagnostic coverage and reimbursement meeting held in Boston. It was great to connect (special shout out to Dr. Mark Hiatt for agreeing to be in our team photo) and learn from so many. We are already looking forward to the next event!

$IMDX

🌍 Heading to ?IMDxInc is excited to connect with colleagues and thought leaders in transplant diagnostics at this year’...
10/02/2025

🌍 Heading to ?

IMDxInc is excited to connect with colleagues and thought leaders in transplant diagnostics at this year’s ASHI Annual Meeting in Orlando!

📍 Visit us at Booth 311

🎤 Don’t miss our Symposium:
“GraftAssureIQ: Enabling In-House dd-cfDNA Testing in Transplant Research”
🗓 Thursday, October 9, 2025
🕐 12:40 pm – 1:35 pm ET
📌 Grand Cypress Ballroom A–C

We’re looking forward to sharing how our GraftAssureIQ™ technology is advancing and supporting the future of in-house dd-cfDNA testing.

See you in Orlando, FL!

American Society for Histocompatibility & Immunogenetics - ASHI

🔗 Click here for more: https://6363663.hs-sites.com/ashi2025

09/24/2025

🚀 Insight Molecular Diagnostics (iMDx) Showcasing Leadership in Kidney Transplant Management

We’re proud to announce that IMDxInc will be presenting our GraftAssure™ technology at two major industry conferences this fall:

📍 Annual Meeting (Singapore) – Sept. 24
Title: “Donor-derived cell-free DNA for Personalized Immunosuppression in Transplantation”
Speakers: Michael Oellerich, MD, (George-August University, Göttingen, Germany), Klemens Budde, MD, (Charité University, Berlin, Germany), and Geoff Bien (iMDx)
Date: Wednesday, September 24, 2025
Time: 12:30 pm -1:25 pm SGT

📍 Annual Meeting (Orlando, FL) – Oct. 9
Title: “GraftAssureIQ: Enabling In-House dd-cfDNA Testing in Transplant Research”
Speakers: Ryan Andrews (iMDx), Eric Johnson, PhD, (Bio-Rad), Geoff Bien (iMDx), and Ekke Schuetz, MD, PhD (iMDx)
Date: Thursday, Oct 9, 2025
Time: 12:40 pm – 1:35 pm ET

At IATDMCT, we’ll host a highlighting how GraftAssure™ can detect transplant rejection and monitor treatment response, helping bring testing closer to the patient. At American Society for Histocompatibility & Immunogenetics - ASHI , we’ll showcase GraftAssureIQ™, our research-use-only test kit, alongside our partner Bio-Rad Laboratories.

💬 “Kidney transplant management is changing. Emerging medications such as anti-CD38 therapies have a chance at treating transplant rejection, and in-house testing will bring care where it belongs – closer to the patient. Our presentations this fall in both Singapore and Orlando highlight the bright potential of our technology and the strong global interest in our assay.” – Josh Riggs, CEO, iMDx

We look forward to sharing how iMDx is helping shape the future of rejection testing and improving care for kidney transplant patients worldwide.

🔗https://investors.imdxinc.com/news-releases/2025/09-24-2025-120521989

$IMDX

Today is the last day of — and what a week it’s been! 🙌It has been a fantastic conference with a great turnout. We had...
08/06/2025

Today is the last day of — and what a week it’s been! 🙌

It has been a fantastic conference with a great turnout. We had the chance to meet so many amazing people and share insights across the transplant community.

🐻 A special shoutout to our stuffy giveaway winners—thanks for bringing the fun!

🎤 Most importantly: Don’t miss our final today, sharing key clinical findings on dd-cfDNA in transplant diagnostics. This data is helping drive more precise, informed care.

07/30/2025

IMDxInc’s new GraftAssure™ dd-cfDNA combination score significantly improves the ability to predict kidney transplant rejection—offering 78% PPV and 93% NPV. By integrating both relative and absolute measures of donor-derived cfDNA, we’re setting a new standard in diagnostic accuracy and helping reduce unnecessary biopsies.

Catch the late breaking oral abstract on Wednesday, Aug. 6th from 10:45-10:52am (Room 25).

See more here: https://hubs.li/Q03zFpJB0

Catch us at Booth #324 at to learn more about our transplant assays.

Read full press release here: https://hubs.li/Q03zFd140

$IMDX

07/28/2025

🚀 Exciting News from IMDxInc!

On July 28, 2025, iMDx announced a virtual Key Opinion Leader (KOL) event for August 15, 2025 at 4:00 PM ET, featuring Dr. Anthony Langone of Vanderbilt University. He’ll share insights on the evolving role of donor‑derived cell‑free DNA (dd‑cfDNA) in transplant care, and discuss iMDx’s innovative GraftAssure™ family of assays powered by advanced digital PCR technology.

This event also highlights the company’s strategy to enable in‑house testing using lab‑developed tests and future clinical‑use kits. A live Q&A session follows.

🧪 iMDx – democratizing access to molecular diagnostics and transforming transplant monitoring.

📅 Register now and send questions at least 12 hours in advance to: [email protected]

Read full press release here: https://hubs.li/Q03zcMh90

🌟 is here! 🌟Heading to the exhibit hall? Don’t forget to stop by Booth D46 to chat with the IMDxInc team and explore G...
06/29/2025

🌟 is here! 🌟

Heading to the exhibit hall? Don’t forget to stop by Booth D46 to chat with the IMDxInc team and explore GraftAssureIQ™.

🔗 https://hubs.li/Q03v3nF-0

🌍 Headed to in London?Visit IMDxInc at Booth D46 and discover GraftAssureIQ™—our decentralized solution advancing tran...
06/27/2025

🌍 Headed to in London?
Visit IMDxInc at Booth D46 and discover GraftAssureIQ™—our decentralized solution advancing transplant monitoring.

📅 June 29–July 2 | 📍 London, UK
🔗 https://hubs.li/Q03v3mC30

Let’s talk innovation, research, and the future of transplant diagnostics.

06/27/2025

🚨 Attending the 2025 ASHI Educational Workshop in Detroit?
IMDxInc is here—stop by and connect with us at the MotorCity Casino Hotel!

📢 Don’t miss our Presentation Spotlight
🧬 Novel Decentralized dd-cfDNA Testing
📅 June 27 | 🕐 1:15–1:30 PM
🎤 Featuring Jim Fee, MS – Associate Director, Product Market Development

Let’s talk innovation in transplant diagnostics!

06/23/2025

Big news from ! New head-to-head data shows our digital PCR-based test performs on par with NGS-based options for measuring dd-cfDNA in kidney transplant patients.

“Head-to-head data like this is highly valuable as we prepare for commercial launch following expected regulatory approval next year. The study results give us confidence that our platform performs on par with NGS-based options currently on the market” said iMDx CEO Josh Riggs.

Catch the full study data at in London, and stop by booth D46 to learn how GraftAssureIQ™ is helping drive .

Read full press release here: https://hubs.li/Q03tdnvZ0

$IMDX

Address

2 INTERNATIONAL PLZ
Nashville, TN
37217

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Website

Alerts

Be the first to know and let us send you an email when IMDxInc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to IMDxInc:

Shortcuts

Share

Category